BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $15.00 price objective on the stock. BTIG Research’s price objective suggests a potential upside of 396.69% from the stock’s previous close.

Several other equities analysts also recently weighed in on the stock. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $3.02 on Wednesday. The stock has a 50 day moving average price of $3.74 and a 200 day moving average price of $8.91. Tvardi Therapeutics has a one year low of $2.81 and a one year high of $43.65. The stock has a market capitalization of $28.33 million, a price-to-earnings ratio of -0.54 and a beta of 0.16.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.23).

Institutional Investors Weigh In On Tvardi Therapeutics

A number of hedge funds have recently modified their holdings of TVRD. Slate Path Capital LP acquired a new stake in Tvardi Therapeutics during the second quarter worth about $16,427,000. Vanguard Group Inc. boosted its holdings in Tvardi Therapeutics by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after purchasing an additional 20,757 shares during the last quarter. American Financial Group Inc. acquired a new position in Tvardi Therapeutics in the 4th quarter valued at about $962,000. 683 Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $4,107,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Tvardi Therapeutics in the 3rd quarter valued at approximately $6,508,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.